• Home
  • Press
  • AstraZeneca's Enhertu Cancer Treatment Reduced Risk of Disease Progression by 72%

AstraZeneca's Enhertu Cancer Treatment Reduced Risk of Disease Progression by 72%

By The CCM Team

AstraZeneca PLC said Monday that its cancer treatment Enhertu reduced the risk of disease progression or death by 72% in patients with HER2-positive metastatic breast cancer.

HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.

Have a medical story to share? Schedule a Consultation

The U.K. pharmaceutical giant said that the DESTINY-Breast03 Phase 3 trial showed that Enhertu demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed antibody drug conjugate currently approved to treat patients with HER2-positive unresectable--unable to be removed by surgery--and/or metastatic breast cancer previously treated with trastuzumab and a taxane--a type of drug that blocks cell growth.

Read more on the Enhertu webiste

 

 


SHARE THIS POST

Consonant Custom Media
Real Stories. Real Engagement.

NYC

Mike Eisgrau
Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tampa Bay

Stephen A. Smith
Publisher | Creative Director 

This email address is being protected from spambots. You need JavaScript enabled to view it.

CA

John Wark
Consulting Editor | Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.